Long-term effects of cladribine tablets treatment on cognition, relapses, MRI, and safety outcomes in patients with relapsing multiple sclerosis: 4-year results from the CLARIFY-MS Extension study

被引：0
|
作者：
Selmaj, Krzysztof [1 ,2 ]
Langdon, Dawn [3 ]
Brochet, Bruno [4 ]
Solari, Alessandra [5 ]
Havrdova, Eva Kubala [6 ,7 ]
Patti, Francesco [8 ,9 ]
Piehl, Fredrik [10 ]
Smyk, Andrzej [11 ]
Lehn, Annette [11 ]
Nolting, Axel [11 ]
Montalban, Xavier [12 ]
Lechner-Scott, Jeannette [13 ,14 ]
机构：
[1] Ctr Neurol, Lodz, Poland
[2] Univ Warmia & Mazury, Dept Neurol, Olsztyn, Poland
[3] Royal Holloway Univ London, Dept Psychol, Egham, Surrey, England
[4] Univ Bordeaux, INSERM U 1215, Bordeaux, France
[5] Fdn IRCCS Ist Neurol Carlo Besta, Unit Neuroepidemiol, Milan, Italy
[6] Charles Univ Prague, Med Fac 1, Dept Neurol, Prague, Czech Republic
[7] Ctr Clin Neurosci, Prague, Czech Republic
[8] Univ Catania, Dept Med & Surg Sci & Adv Technol, GF Ingrassia, Catania, Italy
[9] Univ Catania, Azienda Osped Univ Policlin G Rodolico San Marco, Catania, Italy
[10] Karolinska Inst, Dept Clin Neurosci, Stockholm, Sweden
[11] Merck Healthcare KGaA, Darmstadt, Germany
[12] Univ Hosp Vall dHebron, Dept Neurol Neuroimmunol, Ctr Multiple Sclerosis Catalonia Cemcat, Barcelona, Spain
[13] Univ Newcastle, Newcastle, NSW, Australia
[14] John Hunter Hosp, Div Neurol, Newcastle, NSW, Australia
来源：
MULTIPLE SCLEROSIS JOURNAL | 2024年 / 30卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P846/1650
引用
收藏
页码：655 / 657
页数：3
相关论文
共 50 条
  • [11] MRI Outcomes from the Long-term Extension Study of Tolebrutinib in Participants with Relapsing Multiple Sclerosis: 3-Year Results
    Reich, Daniel
    Traboulsee, Anthony
    Oh, Jiwon
    Fox, Robert J.
    Syed, Sana
    Dukovic, Deborah
    Turner, Timothy
    Arnold, Douglas L.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 592 - 592
  • [12] Improvements in quality of life of people with relapsing multiple sclerosis treated with cladribine tablets during the 2-year CLARIFY-MS study: a plain language summary
    Brochet, Bruno
    Solari, Alessandra
    Lechner-Scott, Jeannette
    Piehl, Fredrik
    Langdon, Dawn
    Hupperts, Raymond
    Selmaj, Krzysztof
    Patti, Francesco
    Brieva, Luis
    Maidal, Eva Maria
    Alexandri, Nektaria
    Smyk, Andrzej
    Nolting, Axel
    Montalban, Xavier
    Havrdova, Eva Kubala
    CLARIFY-MS Investigators
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2024, 14 (06) : 193 - 201
  • [13] Safety and clinical efficacy outcomes from the Long-term extension study of tolebrutinib in patients with relapsing multiple sclerosis: 2-year results
    Oh, J.
    Syed, S.
    Orogun, L.
    Xu, Z.
    Turner, T. J.
    Fox, R. J.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 342 - 343
  • [14] MRI, Safety, and Efficacy Outcomes in Patients with Relapsing MS: 18-month Results from the Long-term Extension Study of Tolebrutinib
    Oh, J.
    Fox, R.
    Arnold, D. L.
    Syed, S.
    Orogun, L.
    Dukovic, D.
    Turner, T.
    Traboulsee, A.
    Reich, D.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (1_SUPPL) : 66 - 67
  • [15] Long-term safety and efficacy of teriflunomide in patients with relapsing multiple sclerosis: Results from the TOWER extension study
    Miller, Aaron E.
    Olsson, Tomas P.
    Wolinsky, Jerry S.
    Comi, Giancarlo
    Kappos, Ludwig
    Hu, Xueqiang
    Xu, Xianhao
    Lublin, Alex L.
    Truffinet, Philippe
    Chavin, Jeffrey
    Delhay, Jean-Luc
    Benamor, Myriam
    Purvis, Annie
    Freedman, Mark S.
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2020, 46
  • [16] Long-term management of multiple sclerosis patients treated with cladribine tablets beyond year 4
    Meuth, Sven G.
    Bayas, Antonios
    Kallmann, Boris
    Linker, Ralf
    Rieckmann, Peter
    Wattjes, Mike P.
    Maeurer, Mathias
    Kleinschnitz, Christoph
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (13) : 1503 - 1510
  • [17] Safety and Efficacy of Tolebrutinib from the Long-term Extension Study in Relapsing Multiple Sclerosis: 2.5-Year Results
    Oh, J.
    Syed, S.
    Li, T.
    Salloum, N.
    Turner, T.
    Fox, R.
    EUROPEAN JOURNAL OF NEUROLOGY, 2023, 30 : 642 - 643
  • [18] Long-term Efficacy and Safety of Fingolimod in Japanese Patients with Relapsing Multiple Sclerosis (MS): 3-year Results from a Phase 2 Extension Study
    Kira, J.
    Itoyama, Y.
    Kikuchi, S.
    Hao, Q.
    Kurosawa, T.
    Ueda, K.
    Nagato, K.
    Saida, T.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 (07) : 928 - 929
  • [19] Time to Qualifying Relapse by Previous Disease Modifying Therapy Status in Patients with Relapsing Multiple Sclerosis Treated with Cladribine Tablets over 2 Years in the CLARIFY-MS Study
    Patti, Francesco
    Brochet, Bruno
    Havrdova, Eva Kubala
    Solari, Alessandra
    Hupperts, R. M. M.
    Langdon, Dawn
    Lechner-Scott, Jeannette
    Piehl, Fredrik
    Selmaj, Krzysztof
    Smyk, Andrzej
    Lehn, Annette
    Montalban, Xavier
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 747 - 748
  • [20] Safety and Clinical Efficacy Outcomes from the Long-term Extension Study of Tolebrutinib in Participants with Relapsing Multiple Sclerosis: 3-Year Results
    Oh, Jiwon
    Reich, Daniel
    Traboulsee, Anthony
    Arnold, Douglas L.
    Syed, Sana
    Dukovic, Deborah
    Vargas, Wendy S.
    Turner, Timothy
    Fox, Robert J.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 334 - 335
12345